title: Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.
abstract: Studies were undertaken to manufacture a multivalent Shigella inactivated whole-cell vaccine that is safe, effective, and inexpensive. By using several formalin concentrations, temperatures, and incubation periods, an optimized set of inactivation conditions was established for Shigella flexneri 2a, S. sonnei, and S. flexneri 3a to produce inactivated whole cells expressing a full repertoire of Ipa proteins and lipopolysaccharide (LPS). The inactivation conditions selected were treatment with 0.2% formalin (S. flexneri 2a and 3a) or 0.6% formalin (S. sonnei) for 48 h at 25°C. Vaccine formulations prepared under different inactivation conditions, in different doses (10E5, 10E7, and 10E9 cells), and with or without the inclusion of double-mutant heat-labile toxin (dmLT) were evaluated in mice. Two intranasal immunizations with ≥10E7 inactivated whole cells resulted in high levels of anti-Invaplex and moderate levels of LPS-specific IgG and IgA in serum and in lung and intestinal wash samples. Addition of dmLT to the vaccine formulations did not significantly enhance humoral immunogenicity. Minimal humoral responses for IpaB, IpaC, or IpaD were detected after immunization with inactivated whole Shigella cells regardless of the vaccine inactivation conditions. In guinea pigs, monovalent formulations of S. flexneri 2a of 3a or S. sonnei consisting of 10E8, 10E9, or 10E10 cells were protective in a keratoconjunctivitis assay. A trivalent formulation provided protection against all three serotypes (S. flexneri 2a, P = 0.018; S. flexneri 3a, P = 0.04; S. sonnei, P < 0.0001). The inactivated Shigella whole-cell vaccine approach incorporates an uncomplicated manufacturing process that is compatible with multivalency and the future development of a broadly protective Shigella vaccine.
authors.affiliation: Department of Subunit Enteric Vaccines and Immunology, Bacterial Disease Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
authors.forename: R W
authors.initials: RW
authors.lastname: Kaminski
authors.forename: M
authors.initials: M
authors.lastname: Wu
authors.forename: K R
authors.initials: KR
authors.lastname: Turbyfill
authors.forename: K
authors.initials: K
authors.lastname: Clarkson
authors.forename: B
authors.initials: B
authors.lastname: Tai
authors.forename: A L
authors.initials: AL
authors.lastname: Bourgeois
authors.forename: L L
authors.initials: LL
authors.lastname: Van De Verg
authors.forename: R I
authors.initials: RI
authors.lastname: Walker
authors.forename: E V
authors.initials: EV
authors.lastname: Oaks
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D004202:Disinfectants; D005557:Formaldehyde; D006168:Guinea Pigs; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000097:blood; D007422:Intestines / Q000276:immunology; D008168:Lung / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D022281:Shigella Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology* / Q000302:isolation & purification; D012763:Shigella flexneri / Q000276:immunology; D012764:Shigella sonnei / Q000276:immunology; D013696:Temperature; D013997:Time Factors; D014611:Vaccination / Q000379:methods; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000302:isolation & purification
chemical_list: D000907:Antibodies, Bacterial; D004202:Disinfectants; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D022281:Shigella Vaccines; D015164:Vaccines, Inactivated; D005557:Formaldehyde